Novellus, Inc.

[Not Yet Scheduled]
Novellus is an Engineered Cellular Medicine company. We use our patented, high efficiency platforms of mRNA-based Gene Editing (~100% efficiency) & mutation-free Cell Reprogramming (44% efficiency) to create medicines for patients with devastating diseases.
Our lead program is for a rare, devastating dermatology disease, and we plan to enter the clinic in 2020. We have over 40 broad patents for our technology platforms, in vivo delivery data to skin, lungs, eye and brain, and disease model data showing safety and therapeutic effects. Our iPSC-derived, engineered MSC data shows significant therapeutic effects in disease models.
We are seeking strategic partners to co-develop drug candidates and to lead clinical and commercial efforts.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Massachusetts
Company HQ Country:
United States
Year Founded:
2014
Main Therapeutic Focus:
Lead Product in Development:
Gene editing for permanent knockdown of one gene
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
Executive Vice President and Co-founder
Novellus, Inc.